Spiking SARS-CoV-2 antiviral immunity in the respiratory tract

Aaron Silva-Sanchez; Troy D Randall

doi:10.1016/j.it.2022.12.007

Spiking SARS-CoV-2 antiviral immunity in the respiratory tract

Trends Immunol. 2023 Feb;44(2):87-89. doi: 10.1016/j.it.2022.12.007. Epub 2022 Dec 22.

Authors

Aaron Silva-Sanchez¹, Troy D Randall²

Affiliations

¹ Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
² Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: troyrandall@uabmc.edu.

Abstract

The COVID-19 pandemic enabled the successful launch of mRNA-based vaccines that, when given intramuscularly, elicit spike-specific antibodies and prevent severe disease, but do not promote mucosal immunity. New data suggest how to boost systemic immunity and elicit pulmonary immunity in a way that more effectively controls infection and impairs transmission.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
Antiviral Agents
COVID-19*
Humans
Pandemics
Respiratory System
SARS-CoV-2*

Substances

Antiviral Agents
Antibodies, Viral
Antibodies, Neutralizing

Abstract

Publication types

MeSH terms

Substances

Grants and funding